m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway
Open Access
- 2 December 2024
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 51, 102230
Abstract
No abstract availableKeywords
Funding Information
- Inner Mongolia Medical University
- National Natural Science Foundation of China (YKD2022MS012, 81872284)
This publication has 43 references indexed in Scilit:
- METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signalingCell Reports, 2023
- METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stabilityNucleic Acids Research, 2022
- METTL3‐mediated m6A mRNA contributes to the resistance of carbon‐ion radiotherapy in non‐small‐cell lung cancerCancer Science, 2022
- Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapyJournal of Extracellular Vesicles, 2022
- Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cellsMolecular Cell, 2022
- RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogrammingNature Communications, 2021
- Update 2020: Management of Non-Small Cell Lung CancerLung, 2020
- m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancerNature Cell Biology, 2018
- RIG-I: a multifunctional protein beyond a pattern recognition receptorProtein & Cell, 2017
- The JAK-STAT Pathway at TwentyImmunity, 2012